日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

更正：一线治疗晚期黑色素瘤：纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗联合伊匹木单抗：基于 RELATIVITY-047 和 CheckMate 067 试验数据的间接治疗比较

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00452
Long, Georgina V; Lipson, Evan J; Hodi, F Stephen; Ascierto, Paolo A; Larkin, James; Lao, Christopher; Grob, Jean-Jacques; Ejzykowicz, Flavia; Moshyk, Andriy; Garcia-Horton, Viviana; Zhou, Zheng-Yi; Xin, Yiqiao; Palaia, Jennell; McDonald, Laura; Keidel, Sarah; Salvatore, Anthony; Patel, Divya; Sakkal, Leon A; Tawbi, Hussein; Schadendorf, Dirk
黑色素瘤
LAT
发表日期：2025
文献求助 收藏

Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysis

通过无进展生存期的改善预测既往未接受治疗、不可切除或转移性黑色素瘤患者的总生存获益：一项相关性荟萃分析

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1541086
Mohr, Peter; Kurt, Murat; Srinivasan, Swetha; Moshyk, Andriy; Ejzykowicz, Flavia; Serafini, Paul; Pourrahmat, Mir-Masoud; Leung, Lisa
黑色素瘤
发表日期：2025
文献求助 收藏

Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma

CheckMate 9ER 中生活质量的简明语言总结：卡博替尼联合纳武利尤单抗治疗晚期肾细胞癌

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2024.2415786
Cella, David; Motzer, Robert J; Suarez, Cristina; Blum, Steven I; Ejzykowicz, Flavia; Hamilton, Melissa; Wallace, Joel F; Simsek, Burcin; Zhang, Joshua; Ivanescu, Cristina; Choueiri, Toni K; Apolo, Andrea B
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

一线治疗晚期黑色素瘤：纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗联合伊匹木单抗：基于 RELATIVITY-047 和 CheckMate 067 试验数据的间接治疗比较

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.24.01125
Long, Georgina V; Lipson, Evan J; Hodi, F Stephen; Ascierto, Paolo A; Larkin, James; Lao, Christopher; Grob, Jean-Jacques; Ejzykowicz, Flavia; Moshyk, Andriy; Garcia-Horton, Viviana; Zhou, Zheng-Yi; Xin, Yiqiao; Palaia, Jennell; McDonald, Laura; Keidel, Sarah; Salvatore, Anthony; Patel, Divya; Sakkal, Leon A; Tawbi, Hussein; Schadendorf, Dirk
黑色素瘤
LAT
发表日期：2024
文献求助 收藏

The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214

CheckMate 214 研究中晚期肾细胞癌患者的健康相关生活质量与总生存期之间的关系

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyae003
Cella, David; Choueiri, Toni K; Hamilton, Melissa; Blum, Steven I; Ivanescu, Cristina; Karu, Karl; Ejzykowicz, Flavia; Motzer, Robert J
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment

肾细胞癌患者的治疗偏好：一项离散选择实验的结果

期刊:Patient Preference and Adherence
影响因子:2
doi:10.2147/PPA.S460994
Ornstein, Moshe C; Rosenblatt, Lisa C; Yin, Xin; Del Tejo, Viviana; Guttenplan, Sarah B; Ejzykowicz, Flavia; Beusterien, Kathleen; Will, Oliver; Mackie, deMauri S; Skiles, Grace; DeCongelio, Marc
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

对一线治疗晚期肾细胞癌的免疫检查点抑制剂进行分数多项式和标准参数网络荟萃分析的挑战

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2023-0004
Petersohn, Svenja; McGregor, Bradley; Klijn, Sven L; May, Jessica R; Ejzykowicz, Flavia; Kurt, Murat; Dyer, Matthew; Malcolm, Bill; Branchoux, Sébastien; Nickel, Katharina; George, Saby; Kroep, Sonja
肿瘤
肿瘤免疫
肾癌
细胞生物学
免疫/内分泌
发表日期：2023
文献求助 收藏

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

CheckMate 9ER研究中，一线纳武利尤单抗联合卡博替尼对比舒尼替尼治疗晚期肾细胞癌患者的患者报告结局：一项开放标签、随机、3期试验

期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(21)00693-8
Cella, David; Motzer, Robert J; Suarez, Cristina; Blum, Steven I; Ejzykowicz, Flavia; Hamilton, Melissa; Wallace, Joel F; Simsek, Burcin; Zhang, Joshua; Ivanescu, Cristina; Apolo, Andrea B; Choueiri, Toni K
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2022
文献求助 收藏

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

晚期肾细胞癌患者接受纳武利尤单抗联合伊匹木单抗治疗与舒尼替尼治疗的条件生存期和长期疗效比较

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.34180
Motzer, Robert J; McDermott, David F; Escudier, Bernard; Burotto, Mauricio; Choueiri, Toni K; Hammers, Hans J; Barthélémy, Philippe; Plimack, Elizabeth R; Porta, Camillo; George, Saby; Powles, Thomas; Donskov, Frede; Gurney, Howard; Kollmannsberger, Christian K; Grimm, Marc-Oliver; Barrios, Carlos; Tomita, Yoshihiko; Castellano, Daniel; Grünwald, Viktor; Rini, Brian I; McHenry, M Brent; Lee, Chung-Wei; McCarthy, Jennifer; Ejzykowicz, Flavia; Tannir, Nizar M
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2022
文献求助 收藏

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

纳武利尤单抗联合卡博替尼对比舒尼替尼治疗晚期肾细胞癌

期刊:New England Journal of Medicine
影响因子:78.5
doi:10.1056/NEJMoa2026982
Choueiri, Toni K; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Zurawski, Bogdan; Oyervides Juárez, Victor M; Hsieh, James J; Basso, Umberto; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Goh, Jeffrey C; Barrios, Carlos; Richardet, Martin; Porta, Camillo; Kowalyszyn, Rubén; Feregrino, Juan P; Żołnierek, Jakub; Pook, David; Kessler, Elizabeth R; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang, Joshua; Maurer, Matthew A; Simsek, Burcin; Ejzykowicz, Flavia; Schwab, Gisela M; Apolo, Andrea B; Motzer, Robert J
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2021
文献求助 收藏